TCM
DNA icon

Tuttle Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Tuttle Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-342
Closed -$33K – 96
2022
Q2 		$33K Sell
342
-146
-30% -$17.8K 0.09% 84
2022
Q1 		$79K Buy
488
+140
+40% +$27.2K 0.2% 77
2021
Q4 		$116K Buy
+348
New +$165K 0.18% 97

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Tuttle Capital Management's DNA Position: Q3 2022 in Review

Tuttle Capital Management sold out of Ginkgo Bioworks (DNA) in Q3 2022, closing a stake of 342 shares — an estimated $33K sold.

Tuttle Capital Management first reported a position in DNA in Q4 2021 and held it in 3 quarters. The position peaked at $116K in Q4 2021. 278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

  • Tuttle Capital Management reported no remaining Ginkgo Bioworks position as of Q3 2022 after selling out during the quarter.
  • Tuttle Capital Management sold 342 Ginkgo Bioworks shares in Q3 2022, an estimated $33K.
  • Tuttle Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 3 quarters.
  • Tuttle Capital Management's Ginkgo Bioworks position peaked at $116K in Q4 2021.
  • 278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Tuttle Capital Management's 13F filing for Q3 2022, filed 11 Oct 2022.